Journal: BMC Cancer
Article Title: NSDHL contributes to breast cancer stem-like cell maintenance and tumor-initiating capacity through TGF-β/Smad signaling pathway in MCF-7 tumor spheroid
doi: 10.1186/s12885-024-13143-3
Figure Lengend Snippet: NSDHL knockdown reduced the BCSC population with CD44+/CD24 − phenotype and ALDH activity in tumor spheroid-injected xenograft tumor tissues, accompanied by decreased Smad2/3 phosphorylation and SOX2 expression. A-D. Representative flow cytometry histograms, dot plots, and quantification of CD44 + and CD24- cells in control (shCtrl) and NSDHL shRNA (shNSDHL)-transduced MCF-7 tumors ( n = 4). E-F. Representative flow cytometry dot plots and quantification of ALDH + cells in shCtrl- and shNSDHL MCF-7 tumors using ALDEFLUOR assay ( n = 4). G. Representative double immunohistochemistry images of CD44 + and ALDH1A1 + cells in shCtrl and shNSDHL MCF-7 tumors. CD44 (green), ALDH1A1(red). Double CD44+/ALDH1A1 + cells (arrow). H-O. Representative western blot images and quantification data of phopho-Smad2 and 3, Smad2, Smad3, SOX2, and NANOG levels in shNSDHL MCF-7 tumors relative to shCtrl MCF-7 tumors ( n = 5). All graphs show the mean ± standard deviation. * P < 0.05, compared with shCtrl using unpaired t-tests
Article Snippet: shRNA lentiviral particles (shNSDHL) (LPP-HSH103352-LVRU6MH-c-100) and control shRNA lentiviral particles (shCtrl) (LPP-CSHCTR001-LVRU6MH-025-C) were purchased from GeneCopoeia (Rockville, MD, USA).
Techniques: Knockdown, Activity Assay, Injection, Expressing, Flow Cytometry, Control, shRNA, Immunohistochemistry, Western Blot, Standard Deviation